Hepatitis C virus (HCV) is a leading cause of chronic hepatitis and hepatocellular carcinoma worldwide and infects more than 1% of the world's population. Successful vaccine development is pivotal in controlling this global health problem. A system for efficient assembly of HCV structural proteins into HCV-like particles (VLPs) in insect cells has been developed in our laboratory. These non-infectious HCV-like particles had similar morphologic, serologic and biophysical properties as the putative virions isolated from HCV infected humans. In contrast to recombinant subunit vaccines, the viral proteins of HCV-like particles may be presented in a native, virion-like conformation and may therefore be superior in eliciting a protective humoral and cellular immune response. Using HCV-LP as a capture antigen in an enzyme-linked immunosorbant assay (ELISA), anti-HCV antibodies were specifically detected in serum from individuals with acute and chronic HCV infection. The ability of the HCV-LP to elicit immune response in vivo was studied in Balb / c mice and New Zealand White rabbits. A specific and broadly directed humoral immune response against the HCV structural proteins with appearance of anti-HCV antibodies was induced. Because of the particular nature of the antigen, cytoxic T cell response, which has been shown to be important in controlling viral infection, may also be induced. Experiments are under way to analyze this aspect of immune response in mice. We plan to conduct experiments in chimpanzees to test the effectiveness of the HCV-LP as a vaccine candidate. Studies have also been extended to full-length HCV cDNA. A full-length HCV genome was assembled from overlapping cDNA clones. HCV polyprotein was expressed from the recombinant baculovirus with correct processing to yield all the structural and nonstructural HCV proteins at high levels. The nonstructural proteins formed complexes in the perinuclear region of the insect cells, possibly as a replicative intermediate. Experiments are underway to determine whether viruslike particles are produced in insect cells and whether the full-length HCV construct is able to replicate and generate infectious virions in this system. These work will not only facilitate studies into HCV replication but also may provide a tissue culture-based system for generation of candidate vaccines and screening of potential antiviral agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK054503-02
Application #
6105869
Study Section
Special Emphasis Panel (DDB)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Ghany, Marc G; Liang, T Jake (2014) Building bridges and providing transparency to the hepatitis C virus drug approval process. Gastroenterology 147:1201-3
Rotman, Yaron; Liang, T Jake (2009) Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 83:7366-74
Su, Xiaowen; Yee, Leland J; Im, KyungAh et al. (2008) Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 49:184-91
Rhodes, S L; Erlich, H; Im, K A et al. (2008) Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immun 9:328-33
Modi, A A; Liang, T J (2008) Hepatitis C: a clinical review. Oral Dis 14:10-4
Yu, Xuekui; Qiao, Ming; Atanasov, Ivo et al. (2007) Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology 367:126-34
Lutchman, Glen; Danehower, Susan; Song, Byung-Cheol et al. (2007) Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132:1757-66
Liang, T Jake (2007) Shortened therapy for hepatitis C virus genotype 2 or 3--is less more? N Engl J Med 357:176-8
Yee, Leland J; Tang, Yong-Ming; Kleiner, David E et al. (2007) Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology 46:74-83
Feld, Jordan J; Liang, T Jake (2006) Hepatitis C -- identifying patients with progressive liver injury. Hepatology 43:S194-206

Showing the most recent 10 out of 33 publications